C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 316—Orphan DrugsSubpart A—General Provisions

21 C.F.R. § 316.3 (2026)

Definitions

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 ACTIVE · 4 IN 5Y cited 1996–2025 13citing cases
At a glance

Courts have cited this section in 13 opinions since 1996, 4 of them in the last five years.

(a) The definitions and interpretations contained in section 201 of the act apply to those terms when used in this part.

(b) The following definitions of terms apply to this part:

(1) Act means the Federal Food, Drug, and Cosmetic Act as amended by section 2 of the Orphan Drug Act (sections 525-528 (21 U.S.C. 360aa-360dd)).

(2) Active moiety means the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt (including a salt with hydrogen or coordination bonds), or other noncovalent derivative (such as a complex, chelate, or clathrate) of the molecule, responsible for the physiological or pharmacological action of the drug substance.

(3) Clinically superior means that a drug is shown to provide a significant therapeutic advantage over and above that provided by an approved drug (that is otherwise the same drug) in one or more of the following ways:

(i) Greater effectiveness than an approved drug (as assessed by effect on a clinically meaningful endpoint in adequate and well controlled clinical trials). Generally, this would represent the same kind of evidence needed to support a comparative effectiveness claim for two different drugs; in most cases, direct comparative clinical trials would be necessary; or

(ii) Greater safety in a substantial portion of the target populations, for example, by the elimination of an ingredient or contaminant that is associated with relatively frequent adverse effects. In some cases, direct comparative clinical trials will be necessary; or

(iii) In unusual cases, where neither greater safety nor greater effectiveness has been shown, a demonstration that the drug otherwise makes a major contribution to patient care.

(4) Director means the Director of FDA's Office of Orphan Products Development.

(5) FDA means the Food and Drug Administration.

(6) Holder means the sponsor in whose name an orphan drug is designated and approved.

(7) IND means an investigational new drug application under part 312 of this chapter.

(8) Manufacturer means any person or agency engaged in the manufacture of a drug that is subject to investigation and approval under the act or the biologics provisions of the Public Health Service Act (42 U.S.C. 262-263).

(9) Marketing application means an application for approval of a new drug filed under section 505(b) of the act or an application for a biologics license submitted under section 351 of the Public Health Service Act (42 U.S.C. 262).

(10) Orphan drug means a drug intended for use in a rare disease or condition as defined in section 526 of the act.

(11) Orphan-drug designation means FDA's act of granting a request for designation under section 526 of the act.

(12) Orphan-drug exclusive approval or exclusive approval means that, effective on the date of FDA approval as stated in the approval letter of a marketing application for a sponsor of a designated orphan drug, no approval will be given to a subsequent sponsor of the same drug for the same use or indication for 7 years, except as otherwise provided by law or in this part. A designated drug will receive orphan-drug exclusive approval only if the same drug has not already been approved for the same use or indication.

(13) Orphan subset of a non-rare disease or condition (“orphan subset”) means that use of the drug in a subset of persons with a non-rare disease or condition may be appropriate but use of the drug outside of that subset (in the remaining persons with the non-rare disease or condition) would be inappropriate owing to some property(ies) of the drug, for example, drug toxicity, mechanism of action, or previous clinical experience with the drug.

(14) Same drug means:

(i) If it is a drug composed of small molecules, a drug that contains the same active moiety as a previously approved drug and is intended for the same use as the previously approved drug, even if the particular ester or salt (including a salt with hydrogen or coordination bonds) or other noncovalent derivative such as a complex, chelate or clathrate has not been previously approved, except that if the subsequent drug can be shown to be clinically superior to the first drug, it will not be considered to be the same drug.

(ii) If it is a drug composed of large molecules (macromolecules), a drug that contains the same principal molecular structural features (but not necessarily all of the same structural features) and is intended for the same use as a previously approved drug, except that, if the subsequent drug can be shown to be clinically superior, it will not be considered to be the same drug. This criterion will be applied as follows to different kinds of macromolecules:

(A) Two protein drugs would be considered the same if the only differences in structure between them were due to post-translational events or infidelity of translation or transcription or were minor differences in amino acid sequence; other potentially important differences, such as different glycosylation patterns or different tertiary structures, would not cause the drugs to be considered different unless the differences were shown to be clinically superior.

(B) Two polysaccharide drugs would be considered the same if they had identical saccharide repeating units, even if the number of units were to vary and even if there were postpolymerization modifications, unless the subsequent drug could be shown to be clinically superior.

(C) Two polynucleotide drugs consisting of two or more distinct nucleotides would be considered the same if they had an identical sequence of purine and pyrimidine bases (or their derivatives) bound to an identical sugar backbone (ribose, deoxyribose, or modifications of these sugars), unless the subsequent drug were shown to be clinically superior.

(D) Closely related, complex partly definable drugs with similar therapeutic intent, such as two live viral vaccines for the same indication, would be considered the same unless the subsequent drug was shown to be clinically superior.

(15) Sponsor means the entity that assumes responsibility for a clinical or nonclinical investigation of a drug, including the responsibility for compliance with applicable provisions of the act and regulations. A sponsor may be an individual, partnership, corporation, or Government agency and may be a manufacturer, scientific institution, or an investigator regularly and lawfully engaged in the investigation of drugs. For purposes of the Orphan Drug Act, FDA considers the real party or parties in interest to be a sponsor.

[57 FR 62085, Dec. 29, 1992, as amended at 64 FR 402, Jan. 5, 1999; 64 FR 56449, Oct. 20, 1999; 78 FR 35132, June 12, 2013]
The 13 cases that cite 21 C.F.R. § 316.3 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENEagle Pharm., Inc. v. Alex Azar, II, 952 F.3d 323 (D.C. Cir. 2020).
cites § 316.3 3×cited by 34 cases
Where it cites § 316.3
“The FDA has interpreted “such drug” to mean “same drug,” 21 C.F.R. § 316.31 (a), and has determined that a drug is the “same” as a previously approved drug if it shares the same “active moiety”—the same active ingredient—and “is intended for the same use,” 21 C.”
The case’s holding
The agency cannot impose additional requirements beyond statutory criteria for granting marketing exclusivity to a drug designated and approved under the Orphan Drug Act.
Later courts cite it for
“the text leaves no room for the fda to place additional requirements on a drug that has been designated and approved before granting its manufacturer the right to exclusivity.” · 2 citing courts
2
GREENMut. Pharm. Co. v. Iyax Pharm., Inc., 459 F. Supp. 2d 925 (C.D. Cal. 2006).
cites § 316.3 3×cited by 16 cases
Where it cites § 316.3
“21 C.F.R. § 316.3 (b)(12). The regulation further provided a definition for determining when two drugs are the "same drug” and thus the second drug may not be approved for market exclusivity.”
Later courts cite it for
“courts have refused to allow a lanham act claim to proceed where, in order to determine the falsity or misleading nature of the representation at issue, the court would be required to interpret and then apply ffdca statutory or regulatory provisions.” · 3 citing courts
3
cites § 316.3 5×cited by 5 cases
Where it cites § 316.3
“One of the regulations, 21 C.F.R. § 316.3 (b)(13)(i), provided a definition for determining when two drugs are the “same drug” and thus the second drug may not be approved for market exclusivity.”
Later courts cite it for
“when the potential market for a drug is small because the target market is relatively small, it is difficult for a pharmaceutical manufacturer to recover the large research and development costs, and even more difficult to realize a worthwhile return on that investment.” · 2 citing courts
4
GREENJazz Pharm., Inc. v. Robert F. Kennedy Jr., 141 F.4th 254 (D.C. Cir. 2025).
cites § 316.3 8×cited by 1 case
Where it cites § 316.3
“See 21 C.F.R. § 316.3 (b)(14)(i). In 2017, the Congress amended the ODA’s exclusivity provision, replacing the phrase “such drug” with “same drug.”
Later courts cite it for
“the words of a statute must be read in their context and with a view to their place in the overall statutory scheme.” · 2 citing courts
5
cites § 316.3 2×cited by 11 cases
Where it cites § 316.3
“” 21 C.F.R. § 316.3 (b)(13)(i). The insertion of the “same drug” concept into the exclusivity regulations effectively limits the scope of exclusivity protection because under the regulations, only if a new drug uses the same active ingredient (“active moiety”) to treat the same…”
6
GREENCatalyst Pharm., Inc. v. Xavier Becerra, 14 F.4th 1299 (11th Cir. 2021).
cites § 316.3 1×cited by 10 cases
Where it cites § 316.3
“” 21 C.F.R. § 316.3 (b)(14)(i). “Moiety,” in this context, means the same active ingredient.”
7
GREENBerlex Labs., Inc. v. Food & Drug Admin., 942 F. Supp. 19 (D.D.C. 1996).
cites § 316.3 3×cited by 6 cases
Where it cites § 316.3
“” 21 C.F.R. § 316.3 (b)(13)(ii). The regulations provide further that a- new drug is “clinically superior” if it offers “[g]reater safety in a substantial portion of the target populations_” 21 C.”
Later courts cite it for
“fda's policies and its interpretation of its own regulations will be paid special deference because of the breadth of congress' delegation of authority to fda and because of fda's scientific expertise.” · 2 citing courts
8
GREENSpectrum Pharm., Inc v. Sylvia Burwell, 824 F.3d 1062 (D.C. Cir. 2016).
cites § 316.3 1×cited by 7 cases
Where it cites § 316.3
“21 C.F.R. § 316.3 (b)(12), (14). Spectrum urges that the regulation’s use of the word “intended” required FDA to consider how Sandoz subjectively intended doctors and patients to use its drug when FDA evaluated its ANDA.”
Later courts cite it for
“designed to treat a rare disease or condition that historically received little attention from pharmaceutical companies.” · 2 citing courts
9
GREENBraeburn Inc. v. U.S. Food & Drug Admin., 389 F. Supp. 3d 1 (D.C. Cir. 2019).
cites § 316.3 1×cited by 6 cases
Where it cites § 316.3
“21 C.F.R. §§ 316.3 (b)(14), 316.31(a). Again, resolution of these issues is not necessary here, but merely recognizing them as possibilities adds layers of doubt to Indivior's prognostications.”
10
GREENSigma-Tau Pharm., Inc. v. Schwetz, 288 F.3d 141 (4th Cir. 2002).
cites § 316.3 3×cited by 10 cases
Where it cites § 316.3
“Sigma-Tau asserts that the FDA should have considered “compelling, readily available, objective evidence of the generics’ intended use,” such as market data for Carnitor, dosage forms, and federal drug reimbursement policies, which would have resulted in the generics not being…”
Later courts cite it for
“directed at fda approved-use, not generic competitor intended-use” · 3 citing courts
11
NO FLAGJazz Pharm., Inc. v. Becerra, No. 2023-1819 (D.D.C. Oct. 30, 2024).
cites § 316.3 8×cited by 0 cases
Where it cites § 316.3
“” 21 C.F.R. § 316.3 (b)(14). That definition turns on whether the drug is composed of “small molecules” or “large molecules.”
12
NO FLAGNeurelis Inc. v. Califf, No. 2024-1576 (D.D.C. Feb. 14, 2025).
cites § 316.3 5×cited by 0 cases
Where it cites § 316.3
“” 21 C.F.R. § 316.3 (b)(2). 2 The FDA explained that Libervant’s seven-year period of marketing exclusivity blocked approval of Valtoco’s use in the youngest pediatric patients.”
13
NO FLAGBraeburn Inc. v. United States Food & Drug Admin., No. 2019-0982 (D.D.C. July 22, 2019).
cites § 316.3 1×cited by 0 cases
Where it cites § 316.3
“21 C.F.R. §§ 316.3 (b)(14), 316.31(a). Again, resolution of these issues is not necessary here, but merely recognizing them as possibilities adds layers of doubt to Indivior’s prognostications.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199620102025

One bar per year. Tallest: 2 cases in 2019. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
D.D.C.6D.C. Cir.411th Cir.14th Cir.1C.D. Cal.1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com